How to Get Vitrakvi (larotrectinib) Covered by Blue Cross Blue Shield in Pennsylvania: PA Forms, Appeals, and Success Strategies
Answer Box: Getting Vitrakvi Covered by Blue Cross Blue Shield in Pennsylvania
Vitrakvi (larotrectinib) requires prior authorization from Blue Cross Blue Shield plans in Pennsylvania for NTRK fusion-positive solid tumors. The fastest path to approval: (1) Submit PA with confirmed NTRK fusion testing results and documentation of metastatic/unresectable disease,